State Board of Administration of Florida Retirement System Sells 1,090 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

State Board of Administration of Florida Retirement System decreased its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 6.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,919 shares of the company’s stock after selling 1,090 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Zentalis Pharmaceuticals were worth $321,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Captrust Financial Advisors boosted its holdings in shares of Zentalis Pharmaceuticals by 15,160.0% during the 1st quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock worth $35,000 after buying an additional 758 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in Zentalis Pharmaceuticals in the third quarter worth $48,000. Point72 Hong Kong Ltd bought a new stake in Zentalis Pharmaceuticals in the third quarter valued at $59,000. Metropolitan Life Insurance Co NY raised its holdings in shares of Zentalis Pharmaceuticals by 24.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,828 shares of the company’s stock valued at $61,000 after purchasing an additional 550 shares during the period. Finally, US Bancorp DE boosted its position in shares of Zentalis Pharmaceuticals by 378.9% during the 1st quarter. US Bancorp DE now owns 1,451 shares of the company’s stock worth $67,000 after purchasing an additional 1,148 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZNTL. Stifel Nicolaus dropped their price target on Zentalis Pharmaceuticals from $46.00 to $45.00 in a research note on Thursday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 2nd. Finally, Jefferies Financial Group reduced their price target on shares of Zentalis Pharmaceuticals from $120.00 to $70.00 in a research report on Friday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $46.00.

Zentalis Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:ZNTL opened at $26.35 on Friday. The stock has a market cap of $1.57 billion, a PE ratio of -6.14 and a beta of 1.84. The stock’s fifty day simple moving average is $20.40 and its two-hundred day simple moving average is $20.72. Zentalis Pharmaceuticals, Inc. has a 1-year low of $15.55 and a 1-year high of $32.34.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last announced its earnings results on Wednesday, May 10th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.11). On average, sell-side analysts forecast that Zentalis Pharmaceuticals, Inc. will post -4.53 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.